VanEck Associates
INVA icon

VanEck Associates’s Innoviva INVA Stock Holding History

VanEck Associates’s Portfolio INVA Stock Details INVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-173,391
Closed -$4.98M – 703
2013
Q4 		$4.98M Buy
+173,391
New +$5.07M 0.03% 234

Other funds holding INVA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VanEck Associates's INVA Position: Q1 2014 in Review

VanEck Associates sold out of Innoviva (INVA) in Q1 2014, closing a stake of 173,391 shares — an estimated $4.98M sold.

VanEck Associates first reported a position in INVA in Q4 2013 and held it in 1 quarter. The position peaked at $4.98M in Q4 2013. 146 funds tracked by Wall St. Rank hold INVA as of Q1 2014.

  • VanEck Associates reported no remaining Innoviva position as of Q1 2014 after selling out during the quarter.
  • VanEck Associates sold 173,391 Innoviva shares in Q1 2014, an estimated $4.98M.
  • VanEck Associates first reported a position in Innoviva in Q4 2013 and held it in 1 quarter.
  • VanEck Associates's Innoviva position peaked at $4.98M in Q4 2013.
  • 146 funds tracked by Wall St. Rank held Innoviva as of Q1 2014.

Based on VanEck Associates's 13F filing for Q1 2014, filed 8 May 2014.